C	C177536	GDC Property Terminology	C158809	Additional Pathologic Findings Question	A section header that includes additional pathologic findings.	additional_pathology_findings	additional pathology findings
C	C177536	GDC Property Terminology	C181710	Average Number of Days per Week One Drinks Alcohol Question	A question regarding the average number of days per week that a subject consumes an alcoholic beverage.	alcohol_days_per_week	alcohol days per week
C	C177536	GDC Property Terminology	C181709	Average Number of Alcoholic Drinks per Day Question	A question regarding the average number of alcoholic beverages a subject consumes per day.	alcohol_drinks_per_day	alcohol drinks per day
C	C177536	GDC Property Terminology	C188000	How Often Have Alcoholic Drink Question	A question about how often an individual has or had a drink containing alcohol.	alcohol_frequency	alcohol frequency
C	C177536	GDC Property Terminology	C127064	Average Number Cigarettes Smoked a Day Question	A question about the average number of cigarettes an individual smoked or smokes in one day.	cigarettes_per_day	cigarettes per day
C	C177536	GDC Property Terminology	C177578	Dysplasia Degree Question	A question about the extent of dysplasia found in a tissue sample.	dysplasia_degree	dysplasia degree
C	C177536	GDC Property Terminology	C177641	Esophageal Columnar Dysplasia Degree Question	A question about the extent of columnar dysplasia found in a esophageal-derived sample.	esophageal_columnar_dysplasia_degree	esophageal columnar dysplasia degree
C	C177536	GDC Property Terminology	C202136	Average Number of Exercise Days per Week Question	A question regarding the average number of days per week a subject exercises.	exercise_frequency_weekly	exercise frequency weekly
C	C177536	GDC Property Terminology	C160837	Is Extranodal Tumor Involvement Present Question	A question about whether extranodal tumor involvement is present.	extranodal_extension	extranodal extension
C	C177536	GDC Property Terminology	C157233	What is the First Presenting Symptom Related to Disease Question	A question about the first symptom that is related to a disease of interest.	first_symptom_prior_to_diagnosis	first symptom prior to diagnosis
C	C177536	GDC Property Terminology	C17357	Gender	Characteristics of people that are socially constructed, including norms, behaviors, and roles based on sex. As a social construct, gender varies from society to society and can change over time. (Adapted from WHO.) IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.	gender	
C	C177536	GDC Property Terminology	C157410	What is the Hormonal Contraceptive Use Status Question	The current status of an individual with regards to contraceptive use.	hormonal_contraceptive_use	hormonal contraceptive use
C	C177536	GDC Property Terminology	C177563	Library Strand Sequenced Question	A question regarding which strand(s) of a library was subjected to nucleic acid sequencing.	library_strand	library strand
C	C177536	GDC Property Terminology	C159824	Is Individual Lost to Follow-Up Question	A question about whether the individual was lost to follow-up.	lost_to_followup	lost to followup
C	C177536	GDC Property Terminology	C159643	Was Lymph Node Dissection Performed Question	A question asking if lymph node dissection was performed during the study.	lymph_nodes_removed	lymph nodes removed
C	C177536	GDC Property Terminology	C160720	Is Lymphatic Invasion Present Question	A question about whether lymphatic invasion is present.	lymphatic_invasion_present	lymphatic invasion present
C	C177536	GDC Property Terminology	C17005	Population Group	A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, sex).	population_group	population group
C	C177536	GDC Property Terminology	C177622	Family Cancer History Relative Sex Question	A request to report the sex of a family member who was diagnosed with a neoplastic disease.	relationship_gender	relationship gender
C	C177536	GDC Property Terminology	C160827	Is Macroscopic Satellite Nodule Present Question	A question about whether the macroscopic satellite nodule is present.	satellite_nodule_present	satellite nodule present
C	C177536	GDC Property Terminology	C177626	Secondhand Smoke Exposure as a Child Question	A question about whether an individual was exposed to secondhand smoke as a child.	secondhand_smoke_as_child	secondhand smoke as child
C	C177536	GDC Property Terminology	C177627	Current Smoking Frequency Question	A question about how often an individual is currently smoking.	smoking_frequency	smoking frequency
C	C177536	GDC Property Terminology	C177628	Time Between Waking and First Smoke Question	A question about the approximate amount of time between the time the individual wakes up in the morning to the time they smoke their first cigarette.	time_between_waking_and_first_smoke	time between waking and first smoke
C	C177536	GDC Property Terminology	C177629	Tobacco Type Used Question	A question about what type(s) of tobacco products an individual has used or is using.	type_of_tobacco_used	type of tobacco used
C	C177536	GDC Property Terminology	C198207	Substance Use Per Day Question	A question regarding the average number of times per day that an individual uses a substance of interest.	use_per_day	use per day
C	C177536	GDC Property Terminology	C127063	Total Years Have Smoked Cigarettes Question	A question about the total years an individual smoked or currently smokes cigarettes.	years_smoked	years smoked
D	C177537	GDC Value Terminology	C4122	Papillary Transitional Cell Carcinoma	A non-invasive or invasive transitional cell carcinoma characterized by a papillary growth pattern. It may occur in the bladder or the renal pelvis.	8130/3 | morphology || Papillary transitional cell carcinoma | primary_diagnosis || Papillary urothelial carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C65182	Micropapillary Transitional Cell Carcinoma	A transitional cell carcinoma characterized by a micropapillary growth pattern. Typical example is the micropapillary variant of infiltrating bladder urothelial carcinoma.	8131/3 | morphology || Transitional cell carcinoma, micropapillary | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C4226	Balloon Cell Nevus	An uncommon variant of melanocytic nevus. It presents as a small pigmented skin lesion. It is characterized by the presence of large melanocytes with clear, foamy or finely vacuolated cytoplasm. It may recur if it is not completely excised.	8722/0 | morphology || Balloon cell nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C3694	Dysplastic Nevus	Solitary or multiple, slightly raised pigmented melanocytic lesions with irregular borders, usually measuring more than 0.6cm in greatest dimension. Morphologically, there is melanocytic atypia and the differential diagnosis from melanoma may be difficult. Patients are at an increased risk for the development of melanoma.	8727/0 | morphology || Dysplastic nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C27007	Spitz Nevus	An acquired or congenital benign skin melanocytic neoplasm. It can occur on any area of the body, but most commonly occurs on the face of children and the thighs of young females. It is characterized by a proliferation of large spindle, oval, or large epithelioid melanocytes in the dermal-epidermal junction. The melanocytic proliferation subsequently extends into the dermis.	8770/0 | morphology || Epithelioid and spindle cell nevus | primary_diagnosis || Juvenile melanoma | primary_diagnosis || Juvenile nevus | primary_diagnosis || Spindle cell nevus, NOS | primary_diagnosis || Spitz nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C20216	Adherent Culture	A type of culture in which cells grow as a monolayer that is attached to the culture substrate.	Adherent Cell Line | specimen_type	C70713	specimen_type
D	C177537	GDC Value Terminology	C114287	ALK/TRK Inhibitor TSR-011	An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.	ALK/TRK Inhibitor TSR-011 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C165598	Anti-CD205 Antibody-drug Conjugate OBT076	An antibody-drug conjugate (ADC) comprised of an anti-CD205 (lymphocyte antigen 75; Ly75) humanized immunoglobin G1 (IgG1) monoclonal antibody conjugated to DM4, a maytansinoid microtubule disruptor, via a cleavable N-succinimidyl-4-(2-pyridyldithio) butanoate (SPDB) linker, with potential antineoplastic activity. Upon intravenous administration, anti-CD205 ADC OBT076 specifically targets and binds to CD205, a receptor involved in antigen capture and endocytosis, expressed on tumor cells. Following rapid internalization of the ADC/CD205 complex, OBT076 releases its DM4 payload due to cleavage of the SPDB linker by intracellular proteases. Then the DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of both cell division and cell growth of CD205-expressing tumor cells. CD205, a type I transmembrane surface glycoprotein belonging to the C-type lectin receptor family, is normally expressed on various antigen-presenting cells (APCs) and some leukocyte sub-populations but it is overexpressed in multiple cancer types where it plays a key role in facilitating metastatic invasion.	Anti-CD205 Antibody-drug Conjugate OBT076 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C162115	Anti-HER2 Bispecific Antibody-drug Conjugate ZW49	An antibody-drug conjugate (ADC) consisting of a bispecific monoclonal antibody (ZW25) directed against two different epitopes of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2, receptor tyrosine-protein kinase erbB-2) linked to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon intravenous administration, anti-HER2 bispecific ADC ZW49 targets and binds to HER2 expressed on tumor cells. Following receptor internalization, the cytotoxic payload is released and induces tumor cell death through an as of yet unknown mechanism of action. Additionally, binding of HER2 may inhibit HER2 activation, HER2 signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Anti-HER2 Bispecific Antibody-drug Conjugate ZW49 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C172391	Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A	An antibody-drug conjugate (ADC) composed of a humanized antibody targeting integrin beta-6 and conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-integrin beta-6/MMAE ADC SGN-B6A targets and binds to integrin beta-6 on the surface of tumor cells. Following internalization of SGN-B6A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in integrin beta-6-expressing tumor cells. Integrin beta-6 is a subunit of integrin alpha-V beta-6 (aVb6). Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.	Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C157481	CDK4/6 Inhibitor BPI-16350	An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor BPI-16350 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.	CDK4/6 Inhibitor BPI-16350 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C171344	CDK4/6 Inhibitor TQB3616	An orally bioavailable, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor TQB3616 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.	CDK4/6 Inhibitor TQB3616 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C175449	c-Met Inhibitor GST-HG161	An orally bioavailable, selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, c-Met inhibitor GST-HG161 targets and binds to c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	c-Met Inhibitor GST-HG161 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C123722	EGFR Antagonist Hemay022	An orally available, irreversible inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, Hemay022 covalently binds to and inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	EGFR Antagonist Hemay022 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C19315	Primary Cell Culture	The cells taken from a tissue source, and their progeny, grown in culture before subdivision and transfer to a sub culture.	Human Original Cells | specimen_type	C70713	specimen_type
D	C177537	GDC Value Terminology	C128250	Pan-AKT Inhibitor ARQ751	An orally bioavailable pan inhibitor of the serine/threonine protein kinase AKT (protein kinase B) enzyme family with potential antineoplastic activity. Upon oral administration, AKT inhibitor ARQ 751 selectively binds to and inhibits the activity of the AKT isoforms 1, 2 and 3, which may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. This may lead to a reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.	Pan-AKT Inhibitor ARQ751 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C170900	PD-L1 Inhibitor GS-4224	An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory, anti-viral and antineoplastic activities. Upon administration, PD-L1 inhibitor GS-4224 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. It may also enhance hepatitis B virus (HBV)-specific CD8+ T-cell function, thereby killing HBV-infected cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells. It is also upregulated in HBV-positive patients and contributes to immune dysfunction against HBV infection.	PD-L1 Inhibitor GS-4224 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C165666	Polymer-conjugated IL-15 Receptor Agonist NKTR-255	A long-acting formulation composed of the human cytokine interleukin-15 (IL-15) that is conjugated by polymers, with potential immunomodulating and anti-tumor activities. Upon administration of polymer-conjugated IL-15 receptor agonist NKTR-255, the IL-15 moiety targets and binds to the alpha subunit of the IL-15 receptor on natural killer (NK) and T-cells, thereby activating the IL-15-mediated pathway. This leads to the expansion and activation of natural killer (NK) cells and memory CD8+ T-cells, thereby enhancing the anti-tumor activity of NKs and long-term memory T-lymphocyte immune responses. This may increase tumor cell killing and decrease tumor cell proliferation. In addition, NKTR-255 may, when combined with a tumor-directed antibody, enhance the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. IL-15 is a pro-inflammatory cytokine that plays a key role in the regulation of T- and NK cell activation, proliferation and promotion of their anti-tumor effects. Compared to IL-15 alone, the polymer formulation allows for increased retention at the tumor site and reduced clearance, thereby increasing the effect of IL-15.	Polymer-conjugated IL-15 Receptor Agonist NKTR-255 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C172988	SHP2 Inhibitor RLY-1971	An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor RLY-1971 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.	SHP2 Inhibitor RLY-1971 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C213296	Papillary Urothelial Carcinoma	An invasive or non-invasive urothelial carcinoma exhibiting papillary growth.	8130/3 | morphology || Papillary transitional cell carcinoma | primary_diagnosis || Papillary urothelial carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C191686	Invasive Micropapillary Urothelial Carcinoma	An invasive urothelial carcinoma exhibiting micropapillary growth pattern.	8131/3 | morphology || Transitional cell carcinoma, micropapillary | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C213115	Balloon Cell Nevus	A melanocytic nevus that arises from the skin or conjunctiva and is characterized by the presence of large melanocytes with clear, foamy, or finely vacuolated cytoplasm.	8722/0 | morphology || Balloon cell nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C213198	Dysplastic Nevus	A slightly raised pigmented melanocytic lesion with irregular borders characterized by the presence of atypical melanocytes. The differential diagnosis from melanoma may be difficult and patients are at an increased risk for the development of melanoma.	8727/0 | morphology || Dysplastic nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C213199	Junctional Nevus	A melanocytic nevus that arises from the skin or conjunctiva. In the skin, it is characterized by the presence of a junctional proliferation of nevus cells without involvement of the dermis. In the conjunctiva, it is characterized by an intraepithelial proliferation of nevus cells.	8740/0 | morphology || Junction nevus | primary_diagnosis || Junctional nevus, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C213114	Compound Nevus	A nevus that arises from the skin or conjunctiva and is characterized by the presence of nevus cells within the epithelium and in the dermis (skin) or substantia propria (conjunctiva).	8760/0 | morphology || Compound nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C213118	Spitz Nevus	An acquired or congenital benign melanocytic neoplasm that occurs in the skin and rarely the conjunctiva and is characterized by a proliferation of large spindle, oval, or large epithelioid melanocytes.	8770/0 | morphology || Epithelioid and spindle cell nevus | primary_diagnosis || Juvenile melanoma | primary_diagnosis || Juvenile nevus | primary_diagnosis || Spitz nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C66758	Spindle Cell Nevus	A Spitz nevus characterized by the presence of spindle-shaped melanocytes.	8772/0 | morphology || Spindle cell nevus, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C38938	Grade 3 Meningioma	A malignant meningioma with aggressive clinical course. It recurs in approximately 50-78% of the cases. This category includes the anaplastic (malignant) meningioma, papillary meningioma, and rhabdoid meningioma.	9530/3 | morphology || Meningioma, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C213642	Adherent Cell Line	A cell line that propagates as a monolayer attached to the surface of a culture vessel.	Adherent Cell Line | specimen_type	C70713	specimen_type
A	C177537	GDC Value Terminology	C169804	Belizatinib	An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon oral administration, belizatinib binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.	ALK/TRK Inhibitor TSR-011 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C199080	Oberotatug Ravtansine	An antibody-drug conjugate (ADC) comprised of an anti-CD205 (lymphocyte antigen 75; Ly75) humanized immunoglobin G1 (IgG1) monoclonal antibody conjugated to DM4, a maytansinoid microtubule disruptor, via a cleavable N-succinimidyl-4-(2-pyridyldithio) butanoate (SPDB) linker, with potential antineoplastic activity. Upon intravenous administration, oberotatug ravtansine specifically targets and binds to CD205, a receptor involved in antigen capture and endocytosis, expressed on tumor cells. Following rapid internalization of the ADC/CD205 complex, oberotatug ravtansine releases its DM4 payload due to cleavage of the SPDB linker by intracellular proteases. Then the DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of both cell division and cell growth of CD205-expressing tumor cells. CD205, a type I transmembrane surface glycoprotein belonging to the C-type lectin receptor family, is normally expressed on various antigen-presenting cells (APCs) and some leukocyte sub-populations but it is overexpressed in multiple cancer types where it plays a key role in facilitating metastatic invasion.	Anti-CD205 Antibody-drug Conjugate OBT076 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C175879	Zanidatamab Zovodotin	An antibody-drug conjugate (ADC) consisting of zanidatamab, a bispecific immunoglobin G1 (IgG1) monoclonal antibody directed against two different epitopes of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via a protease-cleavable linker, to ZD02044, a microtubule-disrupting cytotoxic auristatin, with potential antineoplastic activity. Upon intravenous administration, zanidatamab zovodotin targets and binds to HER2 expressed on tumor cells. Following receptor internalization, ZD02044 is released. It then binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis of HER2-expressing tumor cells. Additionally, binding of HER2 may inhibit HER2 activation, HER2 signaling and HER2-mediated tumor cell growth. HER2, a receptor tyrosine kinase that is mutated or overexpressed in many tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.	Anti-HER2 Bispecific Antibody-drug Conjugate ZW49 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C203047	Sigvotatug Vedotin	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against integrin beta-6 (IB6) conjugated, via a protease-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of sigvotatug vedotin targets and binds to IB6 on the surface of tumor cells. Following internalization, linker cleavage and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in IB6-expressing tumor cells. IB6 is overexpressed in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.	Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C203165	Tibremciclib	An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, tibremciclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.	CDK4/6 Inhibitor BPI-16350 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C203166	Culmerciclib	An orally bioavailable, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, culmerciclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.	CDK4/6 Inhibitor TQB3616 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C184835	Gemnelatinib	An orally bioavailable, selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, gemnelatinib targets and binds to c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	c-Met Inhibitor GST-HG161 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C203119	Sacibertinib	An orally bioavailable, irreversible dual kinase inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2), with potential antineoplastic activity. Upon oral administration, sacibertinib covalently binds to and inhibits the activity of EGFR and HER2. This prevents EGFR/HER2-mediated signaling, which may induce cell death and inhibit tumor growth in EGFR/HER2-overexpressing tumor cells. The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 alterations constitutively upregulate kinase activity.	EGFR Antagonist Hemay022 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C213641	Original Human Cell Specimen	A biospecimen comprised of cells that were isolated directly from a human subject, which may be subsequently cultured and subdivided.	Human Original Cells | specimen_type	C70713	specimen_type
A	C177537	GDC Value Terminology	C175873	Vevorisertib	An orally bioavailable pan inhibitor of the serine/threonine protein kinase AKT (protein kinase B) enzyme family with potential antineoplastic activity. Upon oral administration, vevorisertib selectively binds to and inhibits the activity of the AKT isoforms 1, 2 and 3, which may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. This may lead to a reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.	Pan-AKT Inhibitor ARQ751 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C184828	Evixapodlin	An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory, anti-viral and antineoplastic activities. Upon administration, evixapodlin specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. It may also enhance hepatitis B virus (HBV)-specific CD8+ T-cell function, thereby killing HBV-infected cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells. It is also upregulated in HBV-positive patients and contributes to immune dysfunction against HBV infection.	PD-L1 Inhibitor GS-4224 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C175746	Avipendekin Pegol	A long-acting formulation composed of the human cytokine interleukin-15 (IL-15) that is conjugated by polymers, with potential immunomodulating and anti-tumor activities. Upon administration of avipendekin pegol, the IL-15 moiety targets and binds to the alpha subunit of the IL-15 receptor on natural killer (NK) and T-cells, thereby activating the IL-15-mediated pathway. This leads to the expansion and activation of natural killer (NK) cells and memory CD8+ T-cells, thereby enhancing the anti-tumor activity of NKs and long-term memory T-lymphocyte immune responses. This may increase tumor cell killing and decrease tumor cell proliferation. In addition, NKTR-255 may, when combined with a tumor-directed antibody, enhance the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. IL-15 is a pro-inflammatory cytokine that plays a key role in the regulation of T- and NK cell activation, proliferation and promotion of their anti-tumor effects. Compared to IL-15 alone, the polymer formulation allows for increased retention at the tumor site and reduced clearance, thereby increasing the effect of IL-15.	Polymer-conjugated IL-15 Receptor Agonist NKTR-255 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C199073	Migoprotafib	An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, migoprotafib targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.	SHP2 Inhibitor RLY-1971 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C4106	Acantholytic Squamous Cell Carcinoma	A squamous cell carcinoma characterized by cellular discohesion of the tumor cells that results in the formation of pseudolumina resembling glandular structures.	8075/3 | morphology || Squamous cell carcinoma, acantholytic | primary_diagnosis || Squamous cell carcinoma, adenoid | primary_diagnosis || Squamous cell carcinoma, pseudoglandular | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4030	Urothelial Carcinoma	A carcinoma that arises from the urothelial lining of the urinary tract (bladder, renal pelvis, ureter, or urethra).	8120/3 | morphology || Urothelial carcinoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C65181	Non-Invasive Papillary Urothelial Carcinoma	A urothelial carcinoma characterized by a papillary growth pattern and lack of stromal invasion.	8130/2 | morphology || Papillary transitional cell carcinoma, non-invasive | primary_diagnosis || Papillary urothelial carcinoma, non-invasive | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3190	Linitis Plastica	A condition in which the gastric wall becomes thickened and rubbery (leather-bottle stomach). It is most often associated with diffuse gastric adenocarcinomas.	8142/3 | morphology || Linitis plastica | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3678	Salivary Gland Basal Cell Adenocarcinoma	A rare adenocarcinoma of the major and minor salivary glands, originating from basaloid, myoepithelial, and ductal cells. While morphologically it resembles basal cell carcinoma, it is a distinct entity. The tumor is not encapsulated, may invade locally, and less frequently may metastasize. It usually occurs in older patients.	8147/3 | morphology || Basal cell adenocarcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C201135	Goblet Cell Adenocarcinoma	A rare adenocarcinoma of the digestive system that exhibits neuroendocrine differentiation and is associated with the presence of neoplastic signet-ring cells resembling goblet cells of the intestine.	8243/3 | morphology || 8245/3 | morphology || Adenocarcinoid tumor | primary_diagnosis || Composite carcinoid | primary_diagnosis || Goblet Cell Carcinoid | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27893	Sarcomatoid Renal Cell Carcinoma	A high-grade carcinoma that arises from the kidney. It is not a distinct clinicopathological entity and includes a diverse group of renal cell carcinomas that have been transformed from a lower to a higher grade.	8318/3 | morphology || Renal cell carcinoma, sarcomatoid | primary_diagnosis || Renal cell carcinoma, spindle cell | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7580	Skin Adnexal Adenoma	A benign epithelial neoplasm arising from the sebaceous or sweat glands. Representative examples include sebaceous adenoma, tubular apocrine adenoma, and hidradenoma.	8390/0 | morphology || Adnexal tumor, benign | primary_diagnosis || Skin appendage adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3775	Skin Adnexal Carcinoma	A carcinoma arising from the sebaceous glands, sweat glands, or the hair follicles. Representative examples include sebaceous carcinoma, apocrine carcinoma, eccrine carcinoma, and pilomatrical carcinoma.	8390/3 | morphology || Adnexal carcinoma | primary_diagnosis || Skin appendage carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4615	Benign Skin Adnexal Neoplasm	A neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands. It is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential. Representative examples include cylindroma, hidrocystoma, hidradenoma, and sebaceoma.	8400/3 | morphology || Skin appendage tumor, benign | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C95493	Pancreatic Mucinous-Cystic Neoplasm, High Grade	A non-invasive mucinous cystic neoplasm that arises from the exocrine pancreas and is characterized by the presence of severe dysplasia. The neoplastic columnar mucin-producing epithelial cells form papillae with irregular branching and budding. There is nuclear stratification, prominent nucleoli, and cellular pleomorphism. Mitotic activity is present and the mitoses may be atypical.	8470/2 | morphology || Mucinous cystic neoplasm with high-grade dysplasia | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27949	Metaplastic Carcinoma	A general term used to describe carcinomas arising from epithelial cells that have been transformed into another cell type (metaplastic epithelial cells). A representative example is the adenocarcinoma arising in Barrett esophagus. This term is also used to describe carcinomas in which the malignant epithelial cells show differentiation towards another cell type. A representative example of the latter is the metaplastic breast carcinoma in which the malignant glandular cells show squamous, spindle cell, or chondroid/osseous differentiation.	8575/3 | morphology || Metaplastic carcinoma of no special type | primary_diagnosis || Metaplastic carcinoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7570	Nevus	A neoplasm composed of melanocytes that usually appears as a dark spot on the skin.	8720/0 | morphology || Melanocytic nevus | primary_diagnosis || Nevus, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C205125	Nodular Melanoma	A melanoma that arises from the skin, conjunctiva, and mucosal sites. It is characterized by a vertical growth phase and lacks a significant radial growth phase. It may or may not arise from a pre-existing nevus. Morphologically, it is characterized by the presence of cohesive aggregates of neoplastic melanocytes in the dermis that often exhibit an epithelioid appearance. The overlying epidermis is often involved.	8721/3 | morphology || Nodular melanoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7602	Halo Nevus	A nevus characterized by circumferential depigmentation. It is usually associated with a brisk lymphocytic infiltrate.	8723/0 | morphology || Halo nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7603	Regressing Cutaneous Nevus	A cutaneous nevus associated with focal regression-like changes.	8723/0 | morphology || Regressing nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27095	Cutaneous Nonpigmented Nevus	A cutaneous nevus characterized by the absence of melanin pigment in the melanocytes.	8730/0 | morphology || Achromic nevus | primary_diagnosis || Nonpigmented nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C48622	Mucosal Lentiginous Melanoma	A lentiginous melanoma affecting mucosal surfaces.	8746/3 | morphology || Mucosal lentiginous melanoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3944	Congenital Cutaneous Nevus	A cutaneous nevus that is present at birth. It may present as a small macular, papular, or plaque-like lesion or as a large brown to black hairy skin lesion.	8761/0 | morphology	C176985	morphology
C	C177537	GDC Value Terminology	C66754	Small Cutaneous Congenital Nevus	A cutaneous congenital nevus of small size, with a diameter smaller than 15 mm. It presents as a macular, papular, or plaque-like lesion.	8761/0 | morphology || Small congenital nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4234	Cutaneous Giant Congenital Nevus	A cutaneous congenital nevus that measures more than 200 mm or is unresectable. It usually presents as a dark brown to black hairy lesion. Morphologically, it is characterized by the presence of a compound or intradermal nevus. There is an increased risk of malignant transformation to melanoma, rhabdomyosarcoma, and poorly differentiated malignant tumors.	8761/1 | morphology || Giant pigmented nevus, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C66755	Proliferative Nodules in Cutaneous Congenital Nevus	A benign cutaneous proliferation of epithelioid or spindled melanocytes usually in the upper or mid dermis in a background of congenital nevus. It presents as a dark plaque or nodule above a giant congenital nevus.	8762/1 | morphology || Proliferative dermal lesion in congenital nevus | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4751	Cutaneous Pigmented Spindle Cell Nevus	A subtype of cutaneous Spitz nevus characterized by the presence of heavily pigmented spindle-shaped melanocytes that proliferate in the epidermis or in the epidermis and superficial dermis. It presents as a small and slightly elevated brown or black skin lesion with usually well-demarcated borders. Sometimes the clinical and morphologic features may be difficult to distinguish from melanoma.	8770/0 | morphology || Pigmented spindle cell nevus of Reed | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C6894	Malignant Solitary Fibrous Tumor	A malignant neoplasm of probable fibroblastic derivation characterized by the presence of atypical round to spindle-shaped cells, increased cellularity, necrotic change, and high mitotic activity.	8815/3 | morphology || Solitary fibrous tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3736	Adrenal Gland Myelolipoma	A benign soft tissue lesion that arises from the adrenal gland and is composed of mature adipose and hematopoietic/lymphoid tissues.	8870/0 | morphology || Myelolipoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C126998	Uterine Corpus High Grade Endometrial Stromal Sarcoma	A rare, high-grade sarcoma that arises from the endometrial stroma. It is characterized by round cell morphology. It was previously also known as undifferentiated uterine sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm. It appears to have a prognosis that falls between low grade endometrial stromal sarcoma and undifferentiated sarcoma.	8930/3 | morphology || Endometrial stromal sarcoma, high grade | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4051	Anaplastic (Malignant) Meningioma	A WHO grade 3 meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).	9530/3 | morphology || Meningioma, anaplastic | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3904	Papillary Meningioma	A WHO grade 3 meningioma characterized by the predominance of a perivascular pseudopapillary pattern.	9538/3 | morphology || Papillary meningioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C6909	Rhabdoid Meningioma	A WHO grade 3 meningioma characterized by the predominant presence of rhabdoid cells forming sheets.	9538/3 | morphology || Rhabdoid meningioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4336	Malignant Granular Cell Tumor	An uncommon granular cell tumor that may metastasize to other anatomic sites. Morphologic characteristics include the presence of spindling neoplastic cells, necrosis, extensive pleomorphism, prominent nucleoli, and increased mitiotic activity.	9580/3 | morphology || Granular cell myoblastoma, malignant | primary_diagnosis || Granular cell tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9301	Primary Central Nervous System Lymphoma	A non-Hodgkin or Hodgkin lymphoma that arises from the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.	9590/3 | morphology || Microglioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C7137	Cutaneous Mastocytosis	Mastocytosis that affects the skin. It may manifest as pure cutaneous mastocytosis without extracutaneous involvement or as the result of cutaneous involvement in systemic mastocytosis.	9740/1 | morphology || Cutaneous mastocytosis | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3218	Diffuse Cutaneous Mastocytosis	A rare and most severe variant of cutaneous mastocytosis characterized by generalized skin thickening, erythroderma, dermatographia, and a positive Darier's sign.	9740/1 | morphology || Diffuse cutaneous mastocytosis | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9303	Mastocytoma	A usually localized tumor composed of sheets of mast cells without atypia. It includes the cutaneous mastocytoma which involves the dermis and subcutaneous tissue, and the extracutaneous mastocytoma. Most cases of extracutaneous mastocytoma have been reported in the lung.	9740/1 | morphology || Mastocytoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4037	Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome	An acute myeloid leukemia that develops in patients with a prior history of myelodysplastic syndrome.	9895/3 | morphology || Acute myeloid leukemia with prior myelodysplastic syndrome | primary_diagnosis || Acute myeloid leukemia without prior myelodysplastic syndrome | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4463	Skin Adnexal Neoplasm	A benign or malignant neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands.	Adnexal and Skin Appendage Neoplasms | disease_type	C2991	disease_type
C	C177537	GDC Value Terminology	C1571	Alvocidib Hydrochloride	The hydrochloride salt form of alvocidib, a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.	Alvocidib Hydrochloride | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C150560	Anti-TIM-3 Monoclonal Antibody S095018	A recombinant, fully human monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody S095018 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.	Anti-TIM-3 Monoclonal Antibody Sym023 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C121212	Aprutumab Ixadotin	An antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated, via a non-cleavable linker, to BAY 1168650, an auristatin W derivative and microtubule-disrupting cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, aprutumab ixadotin binds to FGFR2. Upon binding, BAY 1168650 targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in FGFR2-expressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays an essential role in tumor cell proliferation, differentiation and survival.	Aprutumab Ixadotin | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C91073	Ascrinvacumab	A human immunoglobulin G2 (IgG2) monoclonal antibody against activin receptor-like kinase-1 (ALK-1; ALK1), with potential anti-angiogenic and antineoplastic activities. Upon administration, ascrinvacumab targets and binds to ALK-1, and prevents ALK-1 activation by its ligands bone morphogenetic protein 9 (BMP) 9 and BMP10. This prevents ALK-1-mediated endothelial cell signaling and the activation of transforming growth factor-beta (TGF-beta)/TGF-beta receptor I (ALK-5) signaling. This inhibits tumor blood vessel growth, reduces blood flow and angiogenesis and leads to an inhibition of tumor cell proliferation and modulation of the tumor microenvironment (TME). ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor cell types and increases endothelial cell proliferation and migration.	Ascrinvacumab | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C175306	Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140203	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor mimetic (TCRm) construct targeting the immunogenetic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) complexed with human leukocyte antigen (HLA)-A*02 (HLA-A*02/AFP), with potential immunomodulatory and antineoplastic activities. Upon administration, autologous anti-HLA-A*02/AFP TCRm-expressing T-cells ET140203 specifically recognize and selectively bind to AFP peptides presented by HLA-A*02. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of AFP-expressing tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.	Autologous TCRm-expressing T-cells ET140203 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158780	Biopsy with Histologic Confirmation Question	A biopsy with microscopic confirmation.	Biopsy with Histologic Confirmation | evidence_of_progression_type || Biopsy with Histologic Confirmation | evidence_of_recurrence_type || Histologic Confirmation | evidence_of_progression_type || Histologic Confirmation | evidence_of_recurrence_type	C177577 || C198095	evidence_of_recurrence_type || evidence_of_progression_type
C	C177537	GDC Value Terminology	C158782	Convincing Image Source Question	Radiologic evidence that supports a diagnosis.	Convincing Image Source | evidence_of_progression_type || Convincing Image Source | evidence_of_recurrence_type	C177577 || C198095	evidence_of_recurrence_type || evidence_of_progression_type
C	C177537	GDC Value Terminology	C3901	Cutaneous Compound Nevus	A cutaneous nevus composed of neoplastic melanocytes that infiltrate both the epidermis and the dermis.	Dermal and epidermal nevus | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C102754	Ensartinib	An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. In addition, ensartinib inhibits various other kinases, including the receptor tyrosine kinase c-Met (hepatocyte growth factor receptor; HGFR; MET) and the receptor tyrosine kinase C-ros oncogene 1 (ROS1). ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.	Ensartinib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C41449	Epidural Spinal Space	Space between the dura mater and the walls of the vertebral canal.	Epidural Space | biospecimen_anatomic_site || Epidural Space | treatment_anatomic_sites	C171435 || C70729	biospecimen_anatomic_site || treatment_anatomic_sites
C	C177537	GDC Value Terminology	C16576	Female	An individual who belongs to the sex that normally produces ova.	female | gender || female | relationship_gender	C17357 || C177622	gender || relationship_gender
C	C177537	GDC Value Terminology	C39789	Hereditary Renal Cell Carcinoma	Renal cell carcinoma that has developed in relatives of patients with a history of renal cell carcinoma.	Hereditary Renal Cell Carcinoma | comorbidities || Hereditary Renal Cell Carcinoma | risk_factors	C16457 || C17103	comorbidities || risk_factors
C	C177537	GDC Value Terminology	C101523	Tarloxotinib	A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, tarloxotinib is activated in the hypoxic cells within tumors into an irreversible pan-HER inhibitor via a mechanism of action not yet fully elucidated. As a result, this agent inhibits cellular proliferation and differentiation of tumor cells overexpressing HER kinases, which belong to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. Healthy, normal tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity.	Hypoxia-activated Prodrug TH-4000 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C97961	Immunocytokine PDS01ADC	A recombinant fusion protein consisting of the heavy-chains of the human immunoglobulin G1 (IgG1) monoclonal antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine PDS01ADC binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, PDS01ADC may reduce the toxicity associated with systemic administration of recombinant human IL-12.	Immunocytokine NHS-IL12 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C4231	Cutaneous Junctional Nevus	A cutaneous nevus characterized by the presence of an intraepidermal proliferation of nevus cells. The nevus cells form multiple nests in the dermal-epidermal junction. It presents as a small, slightly raised, pigmented skin lesion.	Intraepidermal nevus | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C20197	Male	An individual who belongs to the sex that normally produces sperm.	male | gender || male | relationship_gender	C17357 || C177622	gender || relationship_gender
C	C177537	GDC Value Terminology	C123830	Porcupine Inhibitor ETC-159	An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, ETC-159 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational palmitoylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers.	Porcupine Inhibitor ETC-1922159 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C211860	Prior to Study/Trial Enrollment	Relating to or occurring before enrollment into a study or trial.	Prior to Study Enrollment | timepoint_category	C198201	timepoint_category
C	C177537	GDC Value Terminology	C199324	Prior to Study/Trial Registration	Relating to or occurring before registration into a study or trial.	Prior to Study Registration | timepoint_category	C198201	timepoint_category
C	C177537	GDC Value Terminology	C158754	Progression of Disease at Recurrence Question	At the time of the progression or recurrence of a disease.	Recurrence/Progression | timepoint_category	C198201	timepoint_category
C	C177537	GDC Value Terminology	C74076	Rexinoid NRX 194204	An orally bioavailable synthetic retinoid X receptor (RXR) agonist with potential antineoplastic, neuroprotective, immunoregulatory, and disease-modifying activities. Upon administration, rexinoid VTP-194204 selectively binds to and activates RXRs thereby activating RXR-mediated signaling pathways and inducing changes in gene expression that leads to cell differentiation, decreases cell proliferation, and induces apoptosis in susceptible cancer cells. VTP-194204 enhances the differentiation of CD4-positive T-lymphocytes into inducible regulatory T cells (iTreg) and suppresses the development of inflammatory T helper 17 (Th17) cells. In addition, VTP-194204 is able to cross the blood-brain barrier (BBB) and induces the differentiation of oligodendrocyte precursor cells (OPCs) into oligodendrocytes, promotes repair of myelin, and enhances the survival of dopaminergic neurons.	Rexinoid NRX 194204 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C156395	Resiquimod Sulfate	The sulfate salt form of resiquimod, a toll-like receptor type 7 and 8 (TLR7/8) agonist, with potential immunostimulating and antineoplastic activities. Upon administration, resiquimod targets, binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses. This may lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation.	TLR Agonist BDB001 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12321	Uterine Adnexa	The accessory structures of the uterus, including the ovaries, fallopian tubes, broad ligament, and the ovarian and uterine ligaments.	Uterine adnexa | progression_or_recurrence_anatomic_site || Uterine adnexa | site_of_resection_or_biopsy || Uterine adnexa | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C82470	Veterinarian	An individual licensed to practice veterinary medicine, usually with a doctorate degree.	Veterinarians | occupation_type	C25193	occupation_type